Amy C. Peterson, CMO, Immuno-oncology at BeiGene, Ltd. (BGNE), sold 33,320 shares at $130.37 ($4.5M) on 2018-12-17, disclosed to the SEC on 2018-12-19.
Open-market sale of $4.5M BGNE by CMO, Immuno-oncology. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $130.37 | 900 | $117K | 2.6% |
| 2 | $131.80 | 2,700 | $356K | 8.0% |
| 3 | $131.80 | 2,700 | $356K | 8.0% |
| 4 | $132.91 | 1,700 | $226K | 5.1% |
| 5 | $133.81 | 1,005 | $134K | 3.0% |
| 6 | $133.81 | 1,005 |
| $134K |
| 3.0% |
| 7 | $135.04 | 778 | $105K | 2.4% |
| 8 | $135.04 | 778 | $105K | 2.4% |
| 9 | $136.24 | 2,296 | $313K | 7.0% |
| 10 | $136.24 | 2,296 | $313K | 7.0% |
| 11 | $136.93 | 480 | $66K | 1.5% |
| 12 | $131.74 | 1,631 | $215K | 4.8% |
| 13 | $131.74 | 1,631 | $215K | 4.8% |
| 14 | $132.70 | 1,897 | $252K | 5.7% |
| 15 | $132.70 | 1,897 | $252K | 5.7% |
| 16 | $133.88 | 2,402 | $322K | 7.2% |
| 17 | $133.88 | 2,402 | $322K | 7.2% |
| 18 | $134.81 | 3,600 | $485K | 10.9% |
| 19 | $135.54 | 611 | $83K | 1.9% |
| 20 | $135.54 | 611 | $83K | 1.9% |
| Total | $133.64 avg | 33,320 | $4.5M | 100% |
| Filing → |
| CTMX | SELL | 2022-07-21 | $11K | — | Filing → |
| BGNE | SELL | 2018-11-13 | $8.8M | — | Filing → |
| BGNE | SELL | 2018-08-24 | $1.3M | — | Filing → |